Our Changing World – Neurogenetics

Two New Zealand patients will be the first participants in the world to join a phase 1 clinical trial to test the safety of a new therapy for myotonic dystrophy – a rare neurogenetic condition. It's one example of how New Zealand’s neurogenetic registry and biobank is helping patients here gain access to international clinical trials. Claire Concannon learns more.